MA38648B1 - Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases - Google Patents
Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinasesInfo
- Publication number
- MA38648B1 MA38648B1 MA38648A MA38648A MA38648B1 MA 38648 B1 MA38648 B1 MA 38648B1 MA 38648 A MA38648 A MA 38648A MA 38648 A MA38648 A MA 38648A MA 38648 B1 MA38648 B1 MA 38648B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- tetrahydrocarbazole
- kinase inhibitors
- carboxamide compounds
- substituted carbazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
L'invention concerne des composés représentés par la formule (i) dans laquelle les deux traits en pointillés représentent, soit deux liaisons simples, soit deux liaisons doubles. Dans cette formule, r1 est f, cl, cn, ou ch3; r2 est cl ou ch3; r3 est c(ch3)2oh ou ch2ch2oh; ra est h ou ch3; chaque r6 est indépendamment f, cl, ch3, et/ou och3; et n vaut 0, 1, ou 2. L'invention concerne également, d'une part des procédés d'utilisation de tels composés comme inhibiteurs de la tyrosine kinase de bruton ou "btk" (bruton's tyrosine kinase), et d'autre part des compositions pharmaceutiques comprenant de tels composés. Ces composés conviennent pour le traitement, la prévention, ou le ralentissement de progression, de maladies ou de troubles concernant divers domaines thérapeutiques, tels que ceux des maladies autoimmunes ou des maladies vasculaires.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361839141P | 2013-06-25 | 2013-06-25 | |
PCT/US2014/043978 WO2014210085A1 (fr) | 2013-06-25 | 2014-06-25 | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38648A1 MA38648A1 (fr) | 2017-09-29 |
MA38648B1 true MA38648B1 (fr) | 2018-06-29 |
Family
ID=51210830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38648A MA38648B1 (fr) | 2013-06-25 | 2014-06-25 | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases |
Country Status (31)
Country | Link |
---|---|
US (6) | US9334290B2 (fr) |
EP (1) | EP3013814B1 (fr) |
JP (1) | JP6353529B2 (fr) |
KR (1) | KR102346508B1 (fr) |
CN (1) | CN105358546B (fr) |
AR (1) | AR096721A1 (fr) |
AU (1) | AU2014302548B2 (fr) |
BR (1) | BR112015030723A8 (fr) |
CA (1) | CA2916500A1 (fr) |
CL (1) | CL2015003635A1 (fr) |
CY (1) | CY1119371T1 (fr) |
DK (1) | DK3013814T3 (fr) |
EA (1) | EA026729B1 (fr) |
ES (1) | ES2636652T3 (fr) |
HK (1) | HK1223359A1 (fr) |
HR (1) | HRP20171031T1 (fr) |
HU (1) | HUE034460T2 (fr) |
IL (1) | IL243296B (fr) |
LT (1) | LT3013814T (fr) |
MA (1) | MA38648B1 (fr) |
MY (1) | MY176631A (fr) |
PE (1) | PE20160519A1 (fr) |
PH (1) | PH12015502630A1 (fr) |
PL (1) | PL3013814T3 (fr) |
PT (1) | PT3013814T (fr) |
RS (1) | RS56371B1 (fr) |
SI (1) | SI3013814T1 (fr) |
TN (1) | TN2015000529A1 (fr) |
TW (1) | TWI648272B (fr) |
UY (1) | UY35625A (fr) |
WO (1) | WO2014210085A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201510028PA (en) | 2013-06-25 | 2016-01-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
EP3209652B1 (fr) | 2014-10-24 | 2020-04-15 | Bristol-Myers Squibb Company | Composés atropisomères tricycliques |
RS60312B1 (sr) | 2014-10-24 | 2020-07-31 | Bristol Myers Squibb Co | Jedinjenja indol karboksamida korisna kao inhibitori kinaze |
LT3209651T (lt) * | 2014-10-24 | 2020-01-10 | Bristol-Myers Squibb Company | Karbazolo dariniai |
EP3478148B1 (fr) | 2016-07-01 | 2021-08-04 | Brio Device LLC | Stylet d'intubation à alimentation vidéo |
CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
CN110312713B (zh) * | 2016-12-20 | 2022-08-12 | 百时美施贵宝公司 | 用于制备四氢咔唑甲酰胺化合物的方法 |
JP7331843B2 (ja) | 2018-04-27 | 2023-08-23 | 小野薬品工業株式会社 | Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤 |
EP3829543A1 (fr) | 2018-07-31 | 2021-06-09 | Loxo Oncology, Inc. | Dispersions et formulations séchées par pulvérisation de (s)-5-amino-3-(4-((5-fluoro-2-méthoxybenzamido) méthyle)phényle)-1-(1,1,1-trifluoropropane-2-yl)-1 h-pyrazole-4-carboxamide |
WO2022140246A1 (fr) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Procédés et composés destinés à l'autophagie ciblée |
EP4313023A1 (fr) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Méthodes de traitement combiné de la sclérose en plaques |
WO2023156311A1 (fr) * | 2022-02-15 | 2023-08-24 | F. Hoffmann-La Roche Ag | Procédés pour la préparation de dérivés de 1,2,3,5,6,7-hexahydro-s-indacène |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
CA2140722A1 (fr) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline-thromboxane-synthetase |
WO2005014599A1 (fr) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes |
US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005047290A2 (fr) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Certaines imidazo[1,2-a]pyrazin-8-ylamines, procede de fabrication et methode d'utilisation |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
NZ555681A (en) | 2004-11-10 | 2009-08-28 | Cgi Pharmaceuticals Inc | Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
KR101317119B1 (ko) | 2004-12-17 | 2013-10-11 | 그렌마크 파머수티칼스 에스. 아. | 염증성 및 알레르기성 장애의 치료에 유용한 신규한헤테로사이클릭 화합물 |
CN101223141A (zh) | 2005-03-10 | 2008-07-16 | Cgi药品股份有限公司 | 特定取代的酰胺,其制备方法和使用方法 |
US20070185184A1 (en) | 2005-09-16 | 2007-08-09 | Serenex, Inc. | Carbazole derivatives |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US8518964B2 (en) | 2005-11-22 | 2013-08-27 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ,インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
SG174810A1 (en) | 2006-09-11 | 2011-10-28 | Matrix Lab Ltd | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
JP5489296B2 (ja) | 2007-12-13 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | Janusキナーゼの阻害剤 |
HRP20220401T3 (hr) | 2008-02-14 | 2022-05-27 | Eli Lilly And Company | Nova vizualizacijska sredstva za detektiranje neurološke disfunkcije |
GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
EP2151441A1 (fr) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Dérivés de béta-carboline en tant que substrats pour une enzyme |
BRPI0922565A2 (pt) * | 2008-12-19 | 2015-12-15 | Bristol Myers Squibb Co | compostos de carbazol carboxamida úteis como inibidores de cinase |
CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
WO2011116867A1 (fr) | 2010-03-26 | 2011-09-29 | Merck Patent Gmbh | Benzonaphthyridinamines en tant qu'inhibiteurs d'autotaxine |
WO2011159857A1 (fr) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Composés de carboline-carboxamide utiles en tant qu'inhibiteurs de kinases |
EP2455378A1 (fr) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées |
CN105330675A (zh) | 2010-11-15 | 2016-02-17 | Viiv保健英国有限公司 | Hiv复制的抑制剂 |
KR101585753B1 (ko) | 2011-05-17 | 2016-01-14 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
WO2013054185A1 (fr) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Dérivés de pyrimidine et de pyridine utiles en thérapie |
-
2014
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 CA CA2916500A patent/CA2916500A1/fr not_active Abandoned
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko active IP Right Grant
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/fr active Application Filing
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja active Active
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/fr active Active
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh active Active
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
- 2016-10-04 HK HK16111549.5A patent/HK1223359A1/zh not_active IP Right Cessation
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-07-05 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38648A1 (fr) | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases | |
MA47043B1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
MA41179A (fr) | Composés inhibiteurs de parg | |
MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
TN2015000168A1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA38391B1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
MA40955B1 (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA31117B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
MA33606B1 (fr) | Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2 | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA37691B1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
MA39524A1 (fr) | 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs | |
TN2014000371A1 (fr) | Dérivés macrocycliques pour le traitement de maladies prolifératives | |
MA52370B1 (fr) | Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6 | |
MA45392B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA44144A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA43263B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs |